Associated Papers
Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia.
Lo Schiavo F et al.
Molecular Cancer, 2025
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
Gutierrez-Camino A et al.
British Journal of Cancer, 2024
38049555 (PubMed )
Supplement: 41416_2023_2511_MOESM1_ESM.pdf
The mutational spectrum of FLT3 gene in acute lymphoblastic leukemia is different from acute myeloid leukemia.
Zhang Y et al.
Cancer Gene Therapy, 2020
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D et al.
International Journal of Molecular Sciences, 2018
Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.
Messina M et al.
Oncotarget, 2016
AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia.
Li C et al.
Molecular Cancer Therapeutics, 2015
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N et al.
Cancer Research, 2009
[Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
Wang LH et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2005
Select a paper to view details